Anzeige
Mehr »
Montag, 16.02.2026 - Börsentäglich über 12.000 News
20 Mio. € Bewertung. Zwei zugelassene Psychedelika-Produkte. NASDAQ-Uplist in Arbeit.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
20 Leser
Artikel bewerten:
(0)

Global Pharmacovigilance Market to Reach US$6.1 bn by 2020 Owing to Increasing Consumption of Drugs: Transparency Market Research

ALBANY, New York, March 18, 2016 /PRNewswire/ --

Transparency Market Research has published a new report on the global pharmacovigilance market. As per the report, the global pharmacovigilance market stood at US$2.4 bn in 2013 and is predicted to reach US$6.1 bn by 2020. The report, titled 'Pharmacovigilance Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020', states that the global pharmacovigilance market is expected to rise at a 14.20% CAGR between 2014 and 2020.

Pharmacovigilance is a crucial component of an effective drug regulation system and is used for evaluating and monitoring adverse drug reactions. Pharmacovigilance activities are essential for conducting clinical research. Currently, the global network of pharmacovigilance centers is operating effectively to assure appropriate functioning of drug safety procedures. The large volume of international adverse drug reaction reports collected and stored in a central database assists the national drug regulatory authorities to improve the safety profiles of various drugs. This is expected to help avoid disasters associated with drugs. Growing expectations regarding the safe use of drugs and increasing health awareness among people have propelled the global pharmacovigilance market in the recent past.

Request Industry Research Sample:http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1729

The growing number of pharmacovigilance centers worldwide is playing a key role in spreading awareness among people about safe use of drugs. Web-based sales of drugs, unavailability of knowledgeable people, and high data security risk are some of the possible factors expected to restrict the growth of the global pharmacovigilance market in the years to come. However, factors such as strict regulatory expectations, immediate need for patient reporting, and tough drug inspection systems are expected to propel the global pharmacovigilance market in the coming few years.

The global pharmacovigilance market is segmented on the basis of phase of drug development, region, type of method, and type of service. Based on phase of drug development, the global pharmacovigilance market is classified into preclinical studies, phase I, phase II, phase III, and phase IV or post-marketing surveillance. In 2013, the phase IV or post-marketing surveillance segment held a 60% share in the global pharmacovigilance market and is expected to maintain its dominant position by 2020. Factors such as the need to conduct risk assessment studies at the time of crucial stages of drug development, development of comparative safety data, and the valuation of medication errors are some of the factors expected to help expand the phase III clinical trial segment in the years to come.

Browse Research Report with TOC & Free Analysis:http://www.transparencymarketresearch.com/pharmacovigilance-market.html

Based on the type of service, the global pharmacovigilance market was dominated by the outsourcing segment, accounting for more than 50% of the total pharmacovigilance market, in 2013. By region, in 2013, North America held the largest share of 35% in the global pharmacovigilance market.

The global pharmacovigilance market is highly competitive and fragmented. The rapid growth of the global pharmacovigilance market is expected to attract many CROs and BPOs from across the world. Some of the leading players in the global pharmacovigilance market are Covance, Inc., Quintiles Transnational Holdings, Inc., Cognizant Technology Solutions, Pharmaceutical Product Development, LLC, (PPD), Novartis International AG, PAREXEL International Corporation, F. Hoffmann-La Roche Ltd., Accenture plc, GlaxoSmithKline plc, and Wipro Limited.

Browse Market Research Article:http://www.transparencymarketresearch.com/article/pharmacovigilance-market.htm

Key Segments of Global Pharmacovigilance Market

Pharmacovigilance Market, by Phases of Drug Development

  • Preclinical Studies
  • Phase I
  • Phase II
  • Phase III
  • Phase IV or Post Marketing Surveillance

Pharmacovigilance Market, by Types of Methods

  • Spontaneous Reporting
  • Intensified ADR Reporting
  • Targeted Spontaneous Reporting
  • Cohort Event Monitoring
  • EHR Mining

Pharmacovigilance Market, by Type of Service

  • In-house
  • Contract Outsourcing

Pharmacovigilance Market, by Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the World (RoW)

Other Trending Reports by TMR:

  • Foot and Mouth Disease Vaccines Market:

http://www.transparencymarketresearch.com/foot-mouth-disease-vaccines.html

  • Peptide Therapeutics Market:

http://www.transparencymarketresearch.com/peptide-therapeutics-market.html

About Us:

Transparency Market Research (TMR) is a U.S. based provider of syndicated research, customized research, and consulting services. TMR's global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

Contact:
Mr. Sudip. S
90 State Street, Suite 700
Albany, NY 12207
United States.
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com
Blog: http://www.tmrblog.com/


© 2016 PR Newswire
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.